ANDREW MURPHY - 08 Dec 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research
Signature
/s/**Andrew Murphy
Issuer symbol
REGN
Transactions as of
08 Dec 2023
Transactions value $
$-5,618,842
Form type
4
Filing time
12 Dec 2023, 16:05:00 UTC
Previous filing
06 Dec 2023
Next filing
14 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability $-745,067 -883 -1.49% $843.79 58,538 08 Dec 2023 Direct
transaction REGN Common Stock Award $0 +3,199 +5.46% $0.000000 61,737 08 Dec 2023 Direct F1
transaction REGN Common Stock Tax liability $-4,309,079 -5,105 -8.27% $844.09 56,632 11 Dec 2023 Direct
transaction REGN Common Stock Tax liability $-564,696 -669 -1.18% $844.09 55,963 11 Dec 2023 Direct
holding REGN Common Stock 4,310 08 Dec 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +11,473 $0.000000 11,473 08 Dec 2023 Common Stock 11,473 $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.